The activity of ozonated olive oil against Leishmania major promastigotes

Document Type : Original Article

Authors

1 Department of Medicinal Chemistry, Mashhad University of Medical Sciences, Mashhad, Iran

2 Medical Physics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

3 Mashhad University of Medical Sciences, Mashhad, Iran

4 Cutaneous Leishmaniasis Research Center, Qaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran

Abstract

Objective(s):Cutaneous Leishmaniasis is a common and endemic disease in Khorasan province in North-East of Iran. The pentavalant antimony (Sb V) is the mainstay of treatment that has many side effects and resistance to the drug has been reported. The microbicidal effect of ozone was proven in different microorganisms. Since there is no study in this respect and to achieve a low cost and effective treatment, we decided to evaluate the efficacy of ozone against promastigotes of Leishmania major,in vitro.
Materials and Methods: Ozonated olive oil was prepared after production of ozone by bubbling ozone-oxygen gas produced by ozone generator through olive oil until it solidified. Promastigotes of L. major were cultivated in two phasic media. After calculation of the number of promastigotes, they were incubated with ozonated olive oil (0, 0.626, 0.938, 1.25, 2.5, 5, 10 mcg/ml) at 28 °c for 24 hr. Parasites survival percentage was evaluated using MTS and microscopic assay, and then compared with Glucantime and non-ozonated olive oil.
Results:According to the results, there were significant differences in parasites survival percentage between ozonated olive oil and non-ozonated olive oil, at similar concentrations (P<0.001). Ozonated olive oil was more effective than Glucantime. According to MTS results, Glucantime and ozonated olive oil gel concentrations that are required to inhibit the growth of L. major promastigotes by 50% (IC50), were 165 and 0.002 mg/ml, respectively.
Conclusion: Ozonated olive oil has in vitro activity against the promastigotes of L. major and this effect is dose dependent.

Keywords

References

1. Desjeux P. Leishmaniasis: Current situation and new perspectives. Comp Immunol Microbiol Infect Dis 2004; 27:305-318.
2. Hotez PJ, Molyneux DH, Fenwick A, Ottesen E, Ehrlich Sachs S, Sachs JD. Incorporating a rapid-impact package for neglected tropical diseases with programs for HIV/AIDS, tuberculosis, and malaria. PLoS Med 2006; 3:e102.
3. Hotez PJ, Remme JH, Buss P, Alleyne G, Morel C, Breman JG. Combating tropical infectious diseases: report of the Disease Control Priorities in Developing Countries Project. Clin Infect Dis 2004; 38:871–888.
4. Mohebali M, Javadian E, Yaghoobi-Ershadi MR, Akhavan AA, Hajjaran H, Abaei MR. Characterization of Leishmania infection in rodents from endemic areas of the Islamic Republic of Iran. East Mediterr Health J 2004; 10:591–599.
5. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One 2012; 7:e35671.
6. Klaus SN, Frankenburg S, Ingber A. Epidemiology of cutaneous alaeishmaniasis. Clin Dermatol 1999; 17:257-260.
7. Global Health-Division of Parasitic Diseases and Malaria. Resources for health professionals. C 2010 [updated 2010 Nov 2; cited 2012 Dec 2]. Available at:http://www.cdc.gov/parasites/leishmaniasis/health_professionals/index.html
8. Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet 2005; 366:1561-1577.
9. Coler RN, Reed SG. Second-generation vaccines against leishmaniasis. Trends Parasitol 2005; 21:244-249.
10. Soto J, Toledo JT. Oral miltefosine to treat new world cutaneous leishmaniasis. Lancet Infect Dis 2007; 7:7.
11. Rojas R, Valderrama L, Valderrama M, Varona MX, Ouellette M, Saravia NG. Resistance to antimony and treatment failure in human leishmania (viannia) infection. J Infect Dis 2006; 193:1375–1383.
12. Hadighi R, Mohebali M, Boucher P, Hajjaran H, Khamesipour A, Ouellette M. Unresponsiveness to glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites. PLoS Med 2006; 3:e162.
13. Pourmohammadi B, Motazedian MH, Handjani F, Hatam GH, Habibi S, Sarkari B. Glucantime efficacy in the treatment of zoonotic cutaneous leishmaniasis. Southeast Asian J Trop Med Public Health 2011; 42:502-508.
14. Hadighi R, Boucher P, Khamesipour A, Meamar AR, Roy G, Ouellette M, et al. Glucantime-resistant Leishmania tropica isolated from Iranian patients with cutaneous leishmaniasis are sensitive to alternative antileishmania drugs. Parasitol Res 2007; 101:1319-1322.
15. Kivçak B, Mert T, Ertabaklar H, Balcioğlu IC, Ozensoy Töz S. In vitro activity of Arbutus unedo against Leishmania tropica promastigotes. Turkiye Parazitol Derg 2009; 33: 114-115.
16. Sunnen G. The utilization of ozone for external medical applications. J Adv Med 1998; 1:159-174.
17. Gupta AK, Brintnell WC. Sanitization of contaminated footwear from onychomycosis patients using ozone gas: a novel adjunct therapy for treating onychomycosis and tinea pedis? J Cutan Med Surg 2013; 17:243-249.
18. Lin YC, Wu SC. Effects of ozone exposure on inactivation of intra- and extracellular enterovirus 71. Antiviral Res 2006; 70:147-153.
19. Skalska K, Ledakowicz S, Perkowski J, Sencio B. Germicidal properties of ozonated sunflower oil. Ozone-Sci Eng 2009; 31:232-237.
20. Bocci V, Aldinucci C. Biochemical modifications induced in human blood by oxygenation-ozonation. J Biochem Mol Toxicol 2006; 20:133–138.
21. Travagli V, Zanardi I, Silvietti A, Bocci V. A physicochemical investigation on the effects of ozone on blood. Int J Biol Macromol 2007; 41:504–511.
22. Menendez S, Re L, Falcon L, Argote MB, Mendez I, Fernandez D, et al. Safety of topical Oleozon® in the treatment of Tinea pedis: phase IV clinical trial. Int J Ozone Ther 2008; 7:55-59.
23. Sazgarnia A, Zabolinejad N, Layegh P, Rajabi O, Berenji F, Javidi Z, et al. Antileishmania activity of liposomal  clarithromycin against leishmania major  promastigotes. Iran J Basic Med Sci 2012; 15:1005-1014.
24. Menéndez S, Falcón L, Simón DR, Landa N. Efficacy of ozonized sunflower oil in the treatment of tinea pedis. Mycoses 2002; 45:329-332.
25. Coronel B, Duroselle P, Behr H, Moskovtchenko JF, Freney J. In situ decontamination of medical wastes using oxidative agents: a 16-month study in a polyvalent intensive care unit. J Hosp Infect 2002; 50:207-212.
26. Gupta AK, Brintnell W. Ozone gas effectively kills laboratory strains of Trichophyton rubrum and Trichophyton mentagrophytes using an in vitro test system. J Dermatolog Treat 2014; 25:251-255.
27. Meena A, Trivedi HP, Gupta M, Parvez Sh, Likhyani L. Therapeutic applications of ozonated products. Int J Dent Clin 2011; 3:68-69.
28. Sechi LA, Lezcano I, Nunez N, Espim M, Duprè I, Pinna A, et al. Antibacterial activity of ozonized sunflower oil (Oleozon). J Appl Microbiol 2001; 90:279-284.
29. Mohammadi Z, Shalavi S, Soltani MK, Asgary S. A review of the properties and applications of ozone in endodontics: an update. Iran Endod J 2013; 8:40-43.
30. Ledwa O. PhD. Thesis, National center for scientific research, Havana city.
31. Neveen SI, Geweel Y. Antifungal activity of ozonized olive oil (oleozone). Int J Agri Biol 2006; 8:670-675.
32. Azarpazhooh A, Limeback H. The application of ozone in dentistry: a systematic review of literature. J Dent 2008; 36:104-116.
Iranian Journal of Basic Medical Sciences
Volume 18, Issue 9 - Serial Number 9
September 2015
Pages 915-919

Files

Share

How to cite

Statistics